- Charles River Laboratories Publishes 2023 Corporate Citizenship Report
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine
- Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration
- Charles River Laboratories to Present at Barclays Global Healthcare Conference
- Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing
- Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
- Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance
- Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test
- Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors
- Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call
More ▼
Key statistics
On Thursday, Charles River Laboratories International Inc (CRL:NYQ) closed at 270.95, -1.47% below its 52-week high of 275.00, set on Mar 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 269.59 |
---|---|
High | 272.19 |
Low | 267.23 |
Bid | 190.00 |
Offer | 280.00 |
Previous close | 269.37 |
Average volume | 438.85k |
---|---|
Shares outstanding | 51.35m |
Free float | 50.38m |
P/E (TTM) | 29.19 |
Market cap | 13.83bn USD |
EPS (TTM) | 9.23 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:10 BST.
More ▼